We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ergomed Plc | ERGO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1,346.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,346.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 21/3/2023 11:19 by maddox No Dividend but excellent results and in-line with analyst consensus forecasts:Service fee revenue +24% (in-line with analyst consensus forecasts) Gross profit +22% Gross margin +40.7% Adj. EBITDA +11.5% Adj. eps 42.6p (consensus 40.1p) Order book +23% ADAMAS acquisition looks to have bedded-in well and the outlook looks highly positive. So, we have a strongly growing company in a growing market - but growing ahead of that market growth. Postscript: Shares opened at 1020p rose 40p to 1060p but then faltered and dropped down 23p at 997p. interesting reaction to strong results indicative of a risk-off market rather than specific to ERGO. |
Posted at 29/1/2023 11:03 by maddox Richard Barfield has been extremely impressive so very grateful for his contribution to the transformation of ERGO. He will be a difficult act to follow. However, the strategy is set and the execution going exceedingly well so his contribution will be sustained.He has a c. 1m options on shares which is equivalent to about 2% of ERGO, so we'll have to see what he does with these. Hopefully he'll retain a sizeable holding in ERGO and an informal, if not formal, advisory role in future. Apart from that I like to express my thanks as a shareholder and wish him a very long and very, very happy retirement. If you share my sentiments please give this post a thumbs-up. Cheers Maddox |
Posted at 26/1/2023 10:56 by fegger Positive trading update. But no move in share price. Likely due to the still high PE ratio in an era where PEs have reduced a lot. |
Posted at 17/2/2022 17:27 by km18 ...from last year...Company overview: Founded in 1997, Ergomed plc is a specialist services provider for the pharmaceutical industries, covering all phases of clinical development, post-approval pharmacovigilance and medical information. The company operates in more than 100 countries through its Pharmacovigilance and Clinical research Outsourcing service lines. The company has made several acquisitions over the past 5 years. Last three years’ performance is categorized by steady growth in Revenue, gross Profit and adjusted EBITDA and order book growth in 2020 of 55.5%. Acquisition in 2020 was in the USA with ambition to increase market presence for both business lines. Revenue in USA is currently accounting for around 54%, compared to UK’s 14% and EU area 27%. Latest update from the company shows strong trade with 38% growth in revenue in the first half of the year bringing the interim figure to £56m. CRO division generated a staggering 90.7%. Healthy balance sheet and prospects for growth are firmly supported by increase in cash balance to £24.6m and growth in order book at 18% since 01/01/2021....from WealthOracleAM |
Posted at 19/1/2022 10:02 by whittler100 ERGO is an Ex-holding that did exceptionally well for me. However, in this market, I do question the PE valuation ascribed to the businesses by the market. I think that ERGO is a fine business but will wait until the next trading update before I reconsider taking a fresh position. I expect the next trading update to be in eh last week of this month. |
Posted at 05/10/2021 10:59 by piedro Edison Investment Research LimErgomed (ERGO): US is now the biggest market in the mix 4 October 2021 - US is now the biggest market in the mix - FX headwinds, but strong underlying growth - Margins also ‘masked’ by unfavourable FX rate - Valuation: £751m or 1,536p/share - H121 update: Operational momentum continues °° PrimeVigilance: Expanding to Japan °° CRO: Strong post-pandemic rebound continues |
Posted at 01/9/2021 15:21 by bermudashorts Yep Ergo going great guns at the moment. Must be one of the best performing stocks in my portfolio and yet advfn and lse forums are amongst the quietest. |
Posted at 10/8/2021 12:04 by piedro ShareSoc Webinar with Ergomed plc (ERGO) - 29 July 2021... thank you :-) |
Posted at 08/8/2021 18:20 by sharesoc In case you missed our webinar with Ergomed the recording and stockopedia report can be found here: hxxps://www.sharesocTo access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc |
Posted at 31/7/2021 13:31 by etarip See:hxxps://simplywall.s |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
